Sinclair Pharma PLC (LON:SPH) has received an average recommendation of “Buy” from the six analysts that are presently covering the company. Six research analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is GBX 61 ($0.76).

SPH has been the subject of several recent analyst reports. Royal Bank Of Canada reissued an “outperform” rating on shares of Sinclair Pharma PLC in a research note on Thursday, September 15th. Stifel Nicolaus reissued a “buy” rating and issued a GBX 63 ($0.79) price target on shares of Sinclair Pharma PLC in a research note on Wednesday, September 21st. N+1 Singer reissued a “buy” rating on shares of Sinclair Pharma PLC in a research note on Wednesday, October 5th. Peel Hunt reissued a “buy” rating and issued a GBX 68 ($0.85) price target on shares of Sinclair Pharma PLC in a research note on Tuesday, September 27th. Finally, Canaccord Genuity reissued a “buy” rating and issued a GBX 58 ($0.72) price target on shares of Sinclair Pharma PLC in a research note on Friday.

In related news, insider Alan Olby purchased 6,748 shares of the firm’s stock in a transaction that occurred on Monday, November 14th. The stock was acquired at an average price of GBX 29 ($0.36) per share, for a total transaction of £1,956.92 ($2,444.93). Also, insider Jeff Thompson purchased 150,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 4th. The stock was bought at an average price of GBX 29 ($0.36) per share, with a total value of £43,500 ($54,347.83).

Shares of Sinclair Pharma PLC (LON:SPH) opened at 30.25 on Friday. Sinclair Pharma PLC has a one year low of GBX 26.00 and a one year high of GBX 61.33. The company has a 50-day moving average of GBX 28.58 and a 200 day moving average of GBX 30.65. The firm’s market cap is GBX 150.34 million.

About Sinclair Pharma PLC

Sinclair Pharma plc, formerly Sinclair IS Pharma plc, is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in the manufacture and wholesale distribution of dermatological products. Its segments are Country Operations, which include its operations in France, the United Kingdom, Italy, Germany and Spain, and International Operations, under which the Company sells through a local distributor.

Receive News & Stock Ratings for Sinclair Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinclair Pharma PLC and related stocks with our FREE daily email newsletter.